Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme

BACKGROUND: In recent years, PD-1/PD-L1 immune checkpoint inhibitors have improved cancer therapy in many tumor types, but no benefit of immune checkpoint therapy has been found in glioblastoma multiforme (GBM). Based on the results of our earlier work, which showed a reduction of PD-L1 expression i...

Descripción completa

Detalles Bibliográficos
Autores principales: Heynckes, Sabrina, Daka, Karam, Franco, Pamela, Gaebelein, Annette, Frenking, Jan Hendrik, Doria-Medina, Roberto, Mader, Irina, Delev, Daniel, Schnell, Oliver, Heiland, Dieter Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359796/
https://www.ncbi.nlm.nih.gov/pubmed/30709339
http://dx.doi.org/10.1186/s12885-019-5308-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359796/
https://www.ncbi.nlm.nih.gov/pubmed/30709339
http://dx.doi.org/10.1186/s12885-019-5308-y

Ejemplares similares